| Autor: |
Davey, R. A., Su, Gloria M., Hargrave, Rebecca M., Harvie, Rozelle M., Baguley, Bruce C., Davey, Mary W. |
| Zdroj: |
Cancer Chemotherapy & Pharmacology; Feb1997, Vol. 39 Issue 5, p424-430, 7p |
| Abstrakt: |
The effectiveness of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide (DACA) relative to that of amsacrine, idarubicin, daunorubicin and paclitaxel against three different forms of multidrug resistance (MDR) was determined using two sublines of the CCRF-CEM human leukaemia cell line, the P-glycoprotein-expressing CEM/VLB100 subline and the MRP-expressing CEM/E1000 subline, and two extended-MDR sublines of the HL60 human leukaemia cell line, HL60/E8 and HL60/V8. DACA was effective against P-glycoprotein-mediated MDR and MRP- mediated MDR, whereas the extended-MDR pheno- type showed only low levels of resistance (<2-fold) to DACA. In comparison, idarubicin was ineffec- tive against the MRP and extended-MDR phenotypes. Repeated exposure of the K562 human leukaemia cell line to DACA (55, 546 or 1092 n M for 3 days over 10 weeks) did not result in the development of any significant drug resistance. We conclude that DACA has the potential to treat refractory leukaemia. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink